Berenberg Bank analyst Zhiqiang Shu maintained a Hold rating on Amicus (NASDAQ:FOLD) Therapeutics on Friday, setting a price target of $14, which is approximately 39.17% above the present share price of $10.06.
Shu expects Amicus Therapeutics to post earnings per share (EPS) of -$0.25 for the third quarter of 2021.
The current consensus among 6 TipRanks analysts is for a Moderate Buy rating of shares in Amicus, with an average price target of $14.75.
The analysts price targets range from a high of $16 to a low of $14.
In its latest earnings report, released on 03/31/2021, the company reported a quarterly revenue of $66.4 million and a net profit of -$52.58 million. The company's market cap is $2.68 billion.
According to TipRanks.com, Berenberg Bank analyst Zhiqiang Shu is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 14.7% and a 34.92% success rate.
Amicus Therapeutics, Inc. engages in the discovery, development, and commercialization of novel treatments for patients living with rare and orphan diseases. Its product include migalastat HCl, which is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy for fabry disease. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ.